Innervate Therapeutics Ltd (Innervate Tx) is a biotech company focussed on targeted GDNF gene therapies to the CNS for a number of indications including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD) and Spinal Cord Injury (SCI). GDNF is neuroprotective and neurorestorative to motor neurons and a range of neuromodulatory neurons including dopaminergic, noradrenergic, serotoninergic and acetylcholinergic neurons. It’s potent neuroprotective and neurorestorative effects have been shown in pre-clinical models of PD, Multi System Atrophy, ALS, SCI, and epilepsy. However, because its effects are ubiquitous in the CNS it requires very precise delivery to therapeutic targets to avoid potentially harmful side effects. On the other hand, being a relatively large and sticky protein, it diffuses poorly in tissue and effective coverage of therapeutic target volumes is also challenging. Innervate Tx is positioned to maximise the neurorestorative potential of GDNF using patent protected, novel and scalable delivery methods and technology for which it has licenced exclusive use for GDNF gene therapy applications. The company's products and technology exploit the globally recognis